Key result
Corticosteroids, steroid-sparing medications, and devices effectively manage cardiac sarcoidosis despite ongoing guideline gaps.
Why the study?
Cardiac sarcoidosis is a rare, serious condition with heterogeneous presentations that make diagnosis and management challenging, complicated by interindividual variability and the absence of strict guidelines.
This review highlights the multifaceted management of cardiac sarcoidosis, emphasizing the role of corticosteroids, steroid-sparing agents, and device therapies despite the lack of strict guidelines.
Supports individualized use of corticosteroids and devices in cardiac sarcoidosis; leaves open need for standardized guidelines and prospective trials.
Cardiac sarcoidosis (CS) is a rare but serious manifestation of sarcoidosis. Its complications might include high‐grade conduction blocks, atrial and ventricular arrhythmias, and even heart failure. Despite its clinical significance, it exhibits a heterogeneous presentation that makes its diagnosis and management challenging. In this review, we aim to address the different management options of CS, encompassing pharmacotherapy, implantable devices, lifestyle modifications, and surgical interventions. Research findings suggested a positive role of corticosteroids in alleviating the inflammation associated with CS while also improving cardiac parameters. However, given their serious side effects, the use of steroid‐sparing medications was also supported. In addition, device‐based interventions and ablation were effective in managing the increased risk of arrhythmias and heart failure–associated CS. The importance of lifestyle modifications was tackled as a simultaneous treatment option along with the above. Still, interindividual variability and the absence of strict guidelines were major challenges.
No takes yet. Share an insight, caveat, or question.
Alhareth et al. (2026) conducted a review in Cardiac sarcoidosis. Management options (pharmacotherapy, implantable devices, lifestyle modifications, surgical interventions) was evaluated. Corticosteroids, steroid-sparing medications, and device-based interventions are effective in managing cardiac sarcoidosis, though interindividual variability and lack of guidelines remain challenges.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: